Your AI-Trained Oncology Knowledge Connection!
Brentuximab vedotin (BV) induces significantly superior clinical outcomes in patients with CD30-expressing cutaneous T-cell lymphoma (CTCL) as compared with physician's choice with methotrexate or bexarotene, according to a new study presented at the American Society of Hematology Annual Meeting & Exposition, held December 3–6, 2016.
In this interview, Dr. Ivan Borrello talks about a new approach to treating multiple myeloma at the American Society of Hematology Annual Meeting, held December 3–6, 2016.
Obinutuzumab-based therapy is superior to rituximab-based therapy in patients with previously untreated advanced follicular lymphoma.
Pembrolizumab has good activity, is safe and well-tolerated, and induces durable responses in cutaneous T-cell lymphomas, according to a study presented at the American Society of Hematology Annual Meeting & Exposition.
As part of OncoTherapy Network’s coverage of the 58th Annual Meeting & Exposition of the American Society of Hematology (ASH), held December 3–6 in San Diego, California, we spoke with Sean Tracy, MD, PhD, at the Mayo Clinic in Rochester, Minnesota.
As part of our coverage of the ASH Annual Meeting held December 3rd to 6th in San Diego, today we are speaking with Kim Nichols, MD, director of the Cancer Predisposition Division at St. Jude Children's Research Hospital. At this year’s meeting, Dr. Nichols will be participating in a session on genetic susceptibility to leukemia.
As part of OncoTherapy Network’s coverage of the 58th Annual Meeting & Exposition of the American Society of Hematology (ASH), held December 3–6 in San Diego, California, we spoke with oncologist Nicholas J. Short, MD, of the Division of Cancer Medicine at University of Texas MD Anderson Cancer Center, in Houston.
In this interview we discuss results of the CALGB 10603 RATIFY trial of midostaurin for acute myeloid leukemia presented earlier this month at ASH.
Ponatinib offered a better overall survival for chronic myeloid leukemia patients in chronic phase compared with allogeneic stem cell transplantation.
Real-time classification can identify a previously unrecognized subset of high-risk patients with childhood B-cell acute lymphoblastic leukemia who have excellent chances for cure without further intensification of treatment.
Single-agent ibrutinib resulted in significantly improved outcomes for older patients with chronic lymphocytic leukemia, compared with chlorambucil treatment.
Warfarin is an acceptable alternative to low-molecular-weight heparin for patients with cancer-associated thrombosis, according to a new study.
Patients with relapsed or refractory CLL had significant delays in progression and death when idelalisib was added to bendamustine and rituximab.
A new study validates therapeutic guidelines that recommend anticoagulant dose reductions for thrombocytopenia in cancer patients.
Patients with relapsed/refractory multiple myeloma continue to have deep and durable responses to daratumumab plus lenalidomide/dexamethasone.
The oral BCL-2 inhibitor venetoclax elicited a high rate of response from patients with high-risk relapsed or refractory chronic lymphocytic leukemia with 17p deletion.
Children with acute lymphocytic leukemia and their parents commonly over-report the amount of daily oral chemotherapy the child takes to treat the most common blood cancer in children.
Chimeric antigen receptor T cells can eradicate large burdens of multiple myeloma, according to a new study presented at ASH.
Genetic variants increase the risk of osteonecrosis in children under age 10 with acute lymphoblastic leukemia.
Researchers have identified a genetic variant, 2R thymidylate synthase polymorphism, that is associated with an increased risk for avascular necrosis in children with ALL.
In this interview we discuss the role of the tumor microenvironment in Hodgkin and non-Hodgkin lymphoma and research that seeks to disrupt and target this environment as a means of treatment.
Ahead of the 57th ASH Annual Meeting & Exposition, December December 5–8, 2015, Nitin Jain, MD, discusses the cost burden associated with targeted therapy use in the CLL population.
Ahead of the 57th ASH Annual Meeting & Exposition, December 5–8, 2015, Jeffrey Tyner, PhD, discusses his latest research on screening tumor cells derived from cancer patients to help guide better treatment decisions.
Long-term follow-up confirmed the previously reported result that intermittent administration of imatinib is safe and effective in CML patients.
Despite the early trial termination due to safety concerns, an analysis suggests that ponatinib offers improved efficacy over imatinib in newly diagnosed CML.
The addition of daratumumab to traditional therapies used in the treatment of multiple myeloma was well tolerated and associated with high rates of responses.
Autologous hematopoietic cell transplantation is a safe and effective treatment option for patients with HIV-associated lymphoma, according to a study presented at ASH 2014.
Two studies presented at the 2014 ASH Meeting addressed whether an interim PET scan during and after an initial therapy can help guide treatment.
A large trial has shown that adolescents and young adults have better event-free and overall survival when treated on an intensive pediatric ALL regimen.
Early consolidation therapy with brentuximab vedotin after autologous stem cell transplant improved progression-free survival of patients with Hodgkin lymphoma.
